Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Latanoprostene bunod vs Latanoprost in Glaucoma/OHT
NCT00595101Phase 2Completed
- Sponsor
- Bausch + Lomb
- Start
- Dec 2007
- Primary completion
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of latanoprostene bunod in primary open-angle glaucoma (POAG) and ocular hypertension (4 arms), sponsored by Bausch + Lomb. Primary endpoint: Change From Baseline Mean Diurnal Intraocular Pressure (IOP) in the Study Eye at 28 days. Started Dec 2007; status: completed.
02
Drugs
latanoprostene bunod
03
Conditions
primary open-angle glaucoma (POAG)ocular hypertension
Beyond the preview
Go deeper on NCT00595101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00595101.